BE

OXURION to Participate in Upcoming Investor Meetings

Retrieved on: 
Thursday, January 7, 2021

THR-149 has shown positive topline Phase 1 results for the treatment of DME.

Key Points: 
  • THR-149 has shown positive topline Phase 1 results for the treatment of DME.
  • The Company is currently conducting a Phase 2 clinical trial evaluating multiple injections of THR-149 with DME-patients who previously responded sub-optimally to anti-VEGF therapy.
  • Oxurion is headquartered in Leuven, Belgium, and is listed on the Euronext Brussels exchange under the symbol OXUR.
  • This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction.

Celyad Oncology Announces Equity Purchase Agreement for up to $40 Million with Lincoln Park Capital

Retrieved on: 
Thursday, January 7, 2021

LPCs maximum obligation under any single regular purchase will not exceed $2.5 million, unless both parties mutually agree to increase the maximum amount of such purchase.

Key Points: 
  • LPCs maximum obligation under any single regular purchase will not exceed $2.5 million, unless both parties mutually agree to increase the maximum amount of such purchase.
  • Celyad Oncology controls the timing and amount of any future sales of ADSs to LPC.
  • The Purchase Agreement may be terminated by Celyad Oncology at any time, at its sole discretion, without any additional cost or penalty.
  • Additional information regarding the Purchase Agreement with LPC is available in Celyad Oncologys Form 6-K filed with the SEC on January 7, 2021.

Galapagos to present at 39th Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Wednesday, January 6, 2021

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks, uncertainties and other factors that could cause actual results to dier materially from those referred to in the forward-looking statements and, therefore, the reader should not place undue reliance on them.

Key Points: 
  • This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks, uncertainties and other factors that could cause actual results to dier materially from those referred to in the forward-looking statements and, therefore, the reader should not place undue reliance on them.
  • These risks, uncertainties and other factors include, without limitation, the risk that ongoing and future clinical studies with Galapagos compounds may not be completed in the currently envisaged timelines or at all, the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements (including that data from the ongoing and planned clinical research programs may not support registration or further development of Galapagos compounds due to safety, efficacy or other reasons), Galapagos' reliance on collaborations with third parties and that Galapagos estimations regarding its compounds development program and regarding the commercial potential of Galapagos compounds, may be incorrect, as well as those risks and uncertainties identified in our Annual Report on Form 20-F for the year ended 31 December 2019 and our subsequent filings with the SEC.
  • All statements other than statements of historical fact are statements that could be deemed forward-looking statements.
  • The forward-looking statements contained herein are based on managements current expectations and beliefs and speak only as of the date hereof, and Galapagos makes no commitment to update or publicly release any revisions to forward-looking statements in order to reflect new information or subsequent events, circumstances or changes in expectations.

First US patient implanted in the DREAM pivotal IDE study, with the Genio® system for the treatment of Obstructive Sleep Apnea (OSA)

Retrieved on: 
Tuesday, January 5, 2021

The implantation took place at the Nose and Sinus Institute Boca Raton, Floridaand was performed by Dr. Melyssa Hancock, Otolaryngology-Head & Neck surgeon.

Key Points: 
  • The implantation took place at the Nose and Sinus Institute Boca Raton, Floridaand was performed by Dr. Melyssa Hancock, Otolaryngology-Head & Neck surgeon.
  • The DREAM (Dual-sided Hypoglossal neRvE stimulAtion for the treatMent of Obstructive Sleep Apnea) study is a pivotal, Investigational Device Exemption (IDE) trial designed to support the marketing authorization of the Genio system in the United States.
  • Dr. Melyssa Hancock, implanting surgeon from the Nose and Sinus Institute Boca Raton commented: We are very excited to be chosen as the first center in the United States to implant the Genio system in a patient for treatment of obstructive sleep apnea.
  • Enabling US physicians to build their experience with the Genio system, combined with the existing expertise of other international surgeons participating in the DREAM study, is supporting Nyxoahs timeline for the pivotal IDE study enrollment closing by the end of Q2 2021.

Celyad Oncology Announces January 2021 Conference Schedule

Retrieved on: 
Tuesday, January 5, 2021

Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY.

Key Points: 
  • Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY.
  • The Company has received funding from the Walloon Region (Belgium) to support the advancement of its CAR T cell therapy programs.
  • Forward-looking statements may involve known and unknown risks and uncertainties which might cause actual results, financial condition, performance or achievements of Celyad Oncology to differ materially from those expressed or implied by such forward-looking statements.
  • These forward-looking statements speak only as of the date of publication of this document and Celyad Oncologys actual results may differ materially from those expressed or implied by these forward-looking statements.

Selvita completes acquisition of Fidelta from Galapagos

Retrieved on: 
Monday, January 4, 2021

Mechelen, Belgium and Krakow, Poland 04 January 2021, 22.01 TIME CET Galapagos NV (Euronext & NASDAQ: GLPG) and Selvita S.A. (WSE: SLV) announced today that the strategic transaction in which Selvita has acquired Fidelta from Galapagos has been completed.

Key Points: 
  • Mechelen, Belgium and Krakow, Poland 04 January 2021, 22.01 TIME CET Galapagos NV (Euronext & NASDAQ: GLPG) and Selvita S.A. (WSE: SLV) announced today that the strategic transaction in which Selvita has acquired Fidelta from Galapagos has been completed.
  • Selvita has acquired 100% of the outstanding shares in Fidelta for an enterprise value of 31.2M plus the customary adjustments for net cash and working capital.
  • Acquisition of Fidelta substantially expands Selvitas integrated drug discovery services offering and strengthens its position as one of the largest preclinical contract research organizations in Europe.
  • Fidelta will now be fully consolidated under the Selvita Group, it will however continue to operate under the Fidelta name.

Galapagos’ CEO makes donation of €10 million in the form of personal shares to African Parks

Retrieved on: 
Wednesday, December 23, 2020

The 10 million donation will be in the form of ordinary shares of Galapagos, donated by Mr. van de Stolpe to African Parks and spread over the coming five years.

Key Points: 
  • The 10 million donation will be in the form of ordinary shares of Galapagos, donated by Mr. van de Stolpe to African Parks and spread over the coming five years.
  • The first 2 million (25,150 ordinary shares held by Mr. van de Stolpe) have been transferred on 22 December 2020.
  • said Onno van de Stolpe: For me, African Parks is a very worthy cause to contribute to in order to make this happen.
  • We are extremely grateful to Onno in making this very generous commitment to African Parks, where our vision is to make the parks under our management ecologically, socially and financially sustainable, said Peter Fearnhead, CEO of African Parks.

Novadip Biosciences Receives Rare Paediatric Disease Priority Review and Orphan Disease Designation

Retrieved on: 
Wednesday, December 23, 2020

With the support of the Walloon Region, Novadip will be able to extend and consolidate its product platform, including NVD-003 for CPT.

Key Points: 
  • With the support of the Walloon Region, Novadip will be able to extend and consolidate its product platform, including NVD-003 for CPT.
  • The Orphan Status for NVD-003, which is now recognized by the FDA, will allow Novadip to benefit from incentives such as accelerated development, regulatory support, market exclusivity and reduced registration costs.
  • It will also facilitate access to broader clinical indications that are attractive in terms of market potential.
  • Novadip has demonstrated the potential of its technology in CPT, including a case study in a five-year old boy who had failed prior treatments.

Sequana Medical Announces January 2021 Investor Conference Schedule

Retrieved on: 
Thursday, December 17, 2020

Sequana Medical is a commercial stage medical device company developing the alfapump platform for the management of fluid overload in liver disease, malignant ascites and heart failure where diuretics are no longer effective.

Key Points: 
  • Sequana Medical is a commercial stage medical device company developing the alfapump platform for the management of fluid overload in liver disease, malignant ascites and heart failure where diuretics are no longer effective.
  • Building on its proven alfapump platform, Sequana Medical is developing the alfapump DSR, a breakthrough, proprietary approach to fluid overload due to heart failure.
  • Sequana Medical expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release, except if specifically required to do so by law or regulation.
  • You should not place undue reliance on forward-looking statements, which reflect the opinions of Sequana Medical only as of the date of this press release.

Sequana Medical announces January 2021 Investor Conference Schedule

Retrieved on: 
Thursday, December 17, 2020

Sequana Medical is a commercial stage medical device company developing the alfapump platform for the management of fluid overload in liver disease, malignant ascites and heart failure where diuretics are no longer effective.

Key Points: 
  • Sequana Medical is a commercial stage medical device company developing the alfapump platform for the management of fluid overload in liver disease, malignant ascites and heart failure where diuretics are no longer effective.
  • Building on its proven alfapump platform, Sequana Medical is developing the alfapump DSR, a breakthrough, proprietary approach to fluid overload due to heart failure.
  • Sequana Medical expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release, except if specifically required to do so by law or regulation.
  • You should not place undue reliance on forward-looking statements, which reflect the opinions of Sequana Medical only as of the date of this press release.